Resources » World Health Assembly Resolution: Global Action to Advance Health Equity for People with Hemophilia and Other Bleeding Disorders
LINKS
DETAILS

Year: 2026

Language: English

This resource is also available in: French Spanish

Author(s): World Federation of Hemophilia

Format: Video

World Health Assembly Resolution: Global Action to Advance Health Equity for People with Hemophilia and Other Bleeding Disorders

ADDITIONAL INFORMATION

People with bleeding disorders continue to face significant challenges in diagnosis, access to treatment and care around the world. To overcome these challenges, several WHO Member States—led by the government of Armenia, and co-sponsored by the governments of Bosnia & Herzegovina, Egypt, Georgia, Latvia, Malta, Morocco, Nepal, Paraguay, Spain, Sri Lanka and Togo—are leading efforts for the adoption of a dedicated WHA resolution to increase equitable access to diagnosis, treatment and care for people with bleeding disorders across the globe.

The WFH—as a non-state actor in official relations with the WHO since 1969— strongly supports this milestone initiative. This draft resolution, titled Global Action to Advance Health Equity for People with Hemophilia and Other Bleeding Disorders, has been officially proposed by the Member States for discussion and approval at the WHO 158th Session of the Executive Board, taking place in Geneva, Switzerland from February 2 to 7, 2026. This resolution would serve as an official WHO policy document and a commitment by the WHO and the national governments to address the health inequities faced by the bleeding disorders community worldwide.

In this informational webinar you can learn about the latest developments and concrete steps undertaken by the WHO Member States, led by Armenia, to pass this WHA resolution, learn about WFH advocacy in this regard, and find out how you and your organization can support and advocate for this initiative.

Date recorded: January 29, 2026.

The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.

RELATED RESOURCES